269th 'TechBio & BioTech' Investment Summit will take place on May 21st, 2026, converges over 20 senior leaders from family offices and venture capital to dissect the rapid evolution of the life sciences. As the boundaries between computational power and biological discovery blur, this summit moves beyond surface-level trends to explore the core technical and structural shifts driving the next generation of medicine.

In a sector increasingly defined by data-driven breakthroughs, this private video-call provides a strategic forum for healthcare investors to exchange high-level insights. Participants will align on investment strategies that address the complexities of scaling therapeutic platforms and navigating the unique regulatory hurdles of the TechBio landscape.

Participants will:

• Explore where capital is flowing across biotech, medtech, digital health, and wellness
• Discuss strategies for evaluating scalability, clinical traction, and regulatory outlook
• Share perspectives on market timing, impact, and the next generation of investable healthcare ventures
• Engage in one-to-one meetings with peers to foster alignment and potential co-investment

The agenda of the gathering:

• A roundtable discussion with all investors, focused on the topic "Reimagining the role of technology in biology: the most exciting application in TechBio or BioTech you see today"

• A peer-led dialogue around key signals in innovation, regulation, and market demand

• One-to-one meetings for deeper conversations and strategic follow-up

Every Investors Alliance session is a focused, time-efficient gathering built around quality over quantity, connecting serious investors with relevant opportunities in a trusted setting.

Held via video group call on May 21st, 2026, the session runs for 3 hours
(6–9 PM Dubai / 10 AM – 1 PM New York / 4–7 PM Zurich / 7–10 AM California).